Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
J&J agrees to sell Raritan-based blood diagnostics unit for $4 billion
http://www.nj.com/business/index.ssf/2014/03/jj_agrees_to_sell_raritan-based_blood_diagnostics_unit_for_4_billion.html
Well it could be that AMBS must deal with the Carlyle Group for the Raritan-based Ortho-Clinical Diagnostics unit. Quote "Carlyle plans to invest heavily in research and development as well as international expansion."
Could AMBS be negotiating with Carlyle? Well they should be.
They should make a deal or turn to steal.
AMBS - Highway of Gold to Fort Knox
To uplist to Nasdaq the news is so significant over the coming months that this will be the number one stock out of 13,000 stocks out there, so if you own shares, do yourself a favor don't flip out and pay double taxes, just hold on until your financial goals are met because you will not know the day or the hour that this will happen unless of course its tweeted to everyone via Facebook, Twitter, "SocialMedia", its going to be tempting hang on.
Don't let the smart A&& poster change your share holdings.
It could be a very large tax bill coming due dsw.
Sorry for beating up on you, but if you find the light
on this board, do one thing for me. Just Google MANF,
and spend a few minutes looking at the "Outside" research
occurring with that molecule. Just buy 10,000 shares
and go about your business making money.
Or buy, 1,000,000 and play ball on this board.
Yes WarpCore61 we are crossing the Rubicon AMBS is like a Gold Plated Sidewalk to Fort Knox. Never in 20+ years investing in companies have I seen this much in pipeline, not worried about dilution because the big boys who buy 100,000,000 shares will soak it all up. This is a NASDAQ $10-$50 stock one day and it will blow everyones mind because of the MANF molecule is natural and the treatments are almost endless. Heck it should be in bottled water.
Thanks Warpcore, your a wealth of information.
I however, would never ever tweet information before a news story is in AP etc. But thats just me. Maybe in this case its a real show case of how social media is integrating into our investments.
Hope you can hold on for your 50x your money.
Thanks for link - Oh, I keep up Zoomboom, but was not sure about that one fact.
Guess its considered "Public" information at that point.
Should be a tweet link on the Company web site or financial feeds.
Like Yahoo or Ihub that all thanks for the link.
"Release the Dogs of War" Congratulations, everyone for holding on during the Dark hours we have made a turn and the DOGS are Barking.
Blue Horseshoe loves AMBS.
Can someone explain how a CEO tweets,..... pre news?
Its a nice feature, just worried our CEO might be
walking on a very thin layer of ice here.
Can you Tweet the future release of news four days early?
Do you think a story for CNN is in Order here?
CNN likes to cover Alzheimer's tests and solutions.
I let them know somethings up over in AMBS world.
AMBS .078 BIO-TECH CEO TWEETED LYMPRO TEST UPDATE ON MONDAY GAPPER COMMING
Just FYI I like this board, this stock is so low.
Look at PLUG it was .15 cents a year ago. Went to $10.00+
It happens, this company unfortunately has so many flippers
and bad investors who look for 2 cents, when in reality
if we all stuck together like a Band of Brothers, or
band of Brothers & Sisters could hold the line and soak up
the shares. If Bill and Melinda Gates Soak up 200mm shares
and hold for 10 years you can see the dilution can be soaked up
by some smart people, that is why the Cavendish group has
invited AMBS to come and discuss. Hopefully the Old Man
will be there since he is the real ENGINE of this THING
called MANF. The ENGINE of Discovery. Its unfortunate they diluted the shi*t out of this but they had no choice a Football player as CEO and well the Wallstreet types don't like that. If we had a real BIO Tech leader in the Helm the stock would now be over a buck going to ten bucks. But instead we have a group of IHub Cowboy's
rangling over a few hundred thousand or million shares to tout their
holdings like a bunch a monkeys in a Banana Super Market in Costa Rica. I want to make a few million too, but folks we need to work together not fighting about a .07cent stock for gods sake.
This company has truely life changing technology and it will have a superior market cap one of these days.
Will Bill and Melinda Gates Foundation review this?
Via the Cavendish Global Organization, well lets connect the dots,
150 billion, well Bill Gates has half of that covered. So I"m sure
that Bill and Melinda will be reviewing this one very closely.
Should get 2-3 million Grant or performance grant.
Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world. Cavendish Global together with the Global Partnerships Forum and the New York Academy of Sciences organizes the Forum annually in New York.
One only needs to review GANN chart on this site.
The clinical information is coming and when it does,
its going to blow everyones Socks OFF. This MANF
molecule is a worldwide object of study, its red Hot.
When we get to the very soon clinical acceptance for testing
that news could propell this company to the 500million
market cap area 10x higher than now. And thats just the
surface. There is so much potential this stock should be over
a buck right now.
Thanks for Updating the Main page for AMBS on Ihub.
Much appreciated, and more information the better on
this site.
Hi dsw, want to go a round outback? When MANF news goes to Clinical Level 1 testing the stock will be .50 what you going to do then.
Can I request the Board Owners to update the Flow Chart
Natural Treasures somebody, its way out of date.
thanks,
Buying %20-40 more shares on this mild Bio-tech correction.
I'm about loaded landing gear are almost up, will have large load in tow large shares that is. The rest of the non-buyers beware.
LymPro - next big Bio-Tech News
FYI, I bought a 1/4 million shares pitching in.
http://seekingalpha.com/article/1347691-amarantus-lympro-could-be-a-game-changer-for-alzheimers-diagnosis
For all mature investors, buy all you can at these prices.
Read the white papers, research and just shut up if you don't
have anything good to say.
Its old news, its good to review again with so many Lympro bashers around.
Am I missing anything?
Jan 31, 2014
Amarantus Bioscience this week said that it has established a research collaboration with Boston University School of Medicine to evaluate its blood-based protein biomarker LymPro Test for identifying early stage sufferers of neurodegenerative diseases, chronic traumatic encephalopathy, and Alzheimer's disease.
The company will work with Robert Stern, BUSM professor of neurology and neurosurgery and clinical core director at the BU Alzheimer's Disease Center. Stern is currently involved in a National Institutes of Health-funded study looking at methods of detecting CTE.
"We are pleased to be establishing this collaboration to evaluate the potential of LymPro in this emerging area of medical interest," Gerald Commissiong, president and CEO of Amarantus, said in a statement. "While the research is early in nature, there is a strong scientific basis to believe that the cell cycle dysregulation that LymPro measures in Alzheimer's patients may have relevance to traumatic brain injury and CTE."
Financial and other terms of the collaboration were not disclosed.
Amarantus Inks Research Collaboration with BU to Evaluate LymPro Test as CTE, Alzheimer's Dx
http://www.genomeweb.com/proteomics/amarantus-inks-research-collaboration-bu-evaluate-lympro-test-cte-alzheimers-dx
Even selling OTCBB:(PHOT) products as a separate line, would help this company get into the legal area of Colorado as of recently.
Just a separate division. And spin off the Lympro Division as a stock dividend.
Excellent Research On "Seeing how ELPT and AMBS now have Lincoln Park Capital (LPC) financially backing them and relatively similar floats, i.e. 570-Mil. vs. 630-Mil., I am hopeful for a similar run as ELPT's - from $0.09 to $0.95"
The news will come, Lympro will come, its all primed. The series of events are set. Buy all the stock you can get your hands on.
And Investors Hub, if you guys say one more negative thing about us innocent posters out there!
Lets Double our positions. Hold long ship stock certificates.
What ever it takes, this wet soapy dog needs a blow dryer.
Be nice if we can Partner with JNJ, or get the Ball moving.
Purpose of Current Study: This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure
Estimated Enrollment: 620
Study Start Date: March 2014
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
The Trial number for ARCA is NCT01970501
When going to ClinicalTrials.gov enter ARCA
This is for Patient Recruiting.
Some History
Back in 1996, Dr. Michael Bristow, the current CEO of ARCA, was one of the original founders of Myogen. Myogen is considered one of the great biotech success stories of the past 20 years. The company developed a drug called ambrisentan for the treatment of pulmonary arterial hypertension. In 2006, after two successful Phase III trials, but before ambrisentan was submitted to the FDA for approval, Myogen was bought by Gilead Sciences for $2.5 billion.
Myogen was originally funded by the venture capital firm Sequel Ventures. Sequel Ventures was founded by none other than Dan Mitchell, the man who was just appointed to ARCA’s Board of Directors. Mitchell sat on the board of Myogen until it was acquired by Gilead and was instrumental in helping set the company up for the eventual buyout.
After the Myogen sale, Mitchell continued on with Sequel while Dr. Bristow focused on his new venture, Arca Biopharma. My best guess tells me the plan is to repeat at ARCA what worked at Myogen, namely, get Gencaro to a late stage of development and then sell the entire company to one of the majors. The unique, adaptive design of the upcoming trial may allow for that to occur sooner than many anticipate.
Riley McCormack co-owns a small hedge fund here in NYC called Tracer Capital Management. He already owned 2,000,000 shares of ABIO when on 2/4/14 he reported purchasing another 1,000,000 shares on the open market at an average price of $1.70. So he now owns 3,000,000 shares. This was not a hedge fund purchase, as he did it through a personal trust. SEC filings also show he purchased 250,000 warrants with an exercise price of $2.15
Nice to be on the right side congrats
ABIO MGT NEEDS TO FIRE MARKET MAKERS
Blue horseshoe loves ABIO
ARCA'S Gencaro is forecasting to takeover Metoprolol's market consisting of 1+ billion
GENETIC-AF is planned as a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing Gencaro to metoprolol CR/XL for prevention of AF in patients with heart failure and reduced left ventricular ejection fraction (HFREF)
Buy more hear yes all in shorts are of no consequence
ARCA biopharma to Present at Biotech Showcase 2014
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr. Michael R. Bristow, president and chief executive officer, will present at the Biotech Showcase 2014, taking place January 13-15, 2014 in San Francisco, California.
ARCA's corporate presentation is scheduled for Tuesday, January 14, 2014 at 3:00 p.m. Pacific Time. The Company's presentation will be posted in the Investor Relations section of its website (www.arcabiopharma.com) and will also be available via public webcast at: http://www.media-server.com/m/p/3qtnqneu.
This is way under valued now should break out above 5.00
Near term.
Penny super stock in making will wait a few weeks as it settles to buy big
Excellent find
I think like I have said before,
get rid of the quarterback or what ever as CEO,
get a businessman
Look at RXII think business deals matter?
Get a new CEO
What piece of junk
When does this c r a p show some earning power where is mgmt they need to be shaken not stirred !
Lets see some Sales
Look up Nicole Robertson Vp Marketing we have a good team